Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Sandoz Infringes Hospira Sedative Patent, U.S. Judge Rules

May 1 (Bloomberg) -- The Sandoz unit of Swiss drugmaker Novartis AG infringes a U.S. patent licensed by Hospira Inc. for the sedative Precedex, a federal judge in New Jersey decided.

Novartis was sued by Hospira in 2009 in Trenton, New Jersey, over the intravenous medicine, used in surgery. U.S. District Judge Mary L. Cooper decided the case yesterday, according to electronic court records.

Cooper also ruled that Lake Forest, Illinois-based Hospira’s patent “is valid and enforceable,” and said another Hospira patent in the lawsuit is invalid because the purported invention would be obvious to an expert.

The judge also ordered that Sandoz’s planned generic version of the drug can’t be introduced until the infringed patent expires in 2013, according to court papers and U.S. Food and Drug Administration records.

Julie Masow, a spokeswoman for Basel-based Novartis, didn’t immediately return an e-mail message seeking comment on the ruling. Hospira announced the decision in a U.S. Securities and Exchange Commission filing.

The case is Hospira Inc. v. Sandoz International GmbH, 09CV4591, U.S. District Court, District of New Jersey (Trenton).

To see the infringed patent, click: 4,910,214.

To contact the reporter on this story: Phil Milford in Wilmington, Delaware, at

To contact the editor responsible for this story: Michael Hytha at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.